



Metabrain Research – A Partnering Research Organization (PRO) connecting Diabetes & Alzheimer's

Chilly-Mazarin, March 26th 2010 - Metabrain Research is a Partnering Research Organisation (PRO) expert in metabolic diseases orchestrating private & public research ventures. The launch of their website www.metabrainresearch.com this April is the opportunity to present an innovative business model based on a scientific concept connecting metabolic and neurodegenerative diseases.

The PRO concept bears the hallmarks of biotech, CROs and basic research centers. Like a biotech, Metabrain Research proposes innovative drug discovery programs that it aims to partner at early stages with companies able to carry-out clinical developments. Like a CRO, Metabrain has state-of-the art drug discovery capacities covering medicinal chemistry, biology and pharmacology. This aspect is particularly relevant to companies in the metabolic disease area, as many experimental models present at Metabrain are unique. Finally, Metabrain coordinates private/public research ventures and contributes to the valorization of academic research.

The “Metabrain Endeavour” is based on observations found in the literature and exclusive Metabrain data connecting metabolic diseases and neurodegenerative disorders. At the moment, our focus is the link between diabetes and Alzheimer's Disease (AD). Indeed, there are many common features to the two diseases: improper glycemic control, insulin resistance, formation of amyloid plaques, cell death, ... In addition, obese and diabetic patients have an increased risk of developing AD. Finally, metabolic cascades and signaling pathways involved in the progression of both diseases are well known to Metabrain staff, as they have managed the clinical development of compounds affecting these pathways.

This knowledge provides innovative starting-points for the collaborative programs Metabrain offers, which aim to develop novel anti-diabetic compounds as well as drugs targeting the onset of Alzheimer symptoms.

About Metabrain Research

Metabrain Research was created in March 2009, upon the closure of a preclinical R&D centre belonging to Merck Serono, to provide an innovative & sustainable model of early stage drug discovery research.

Based near Paris, in France, Metabrain Research is a PRO of 31 employees, expert in metabolic disorders. It functions as a stand-alone drug discovery unit disposing of chemistry, biology and pharmacology capacities and interacting with biotech, pharma and academia. Metabrain proposes collaborative exploratory research programs linking metabolic and neurodegenerative diseases. Its expertise in diabetes and obesity is also available for contract research.

Contact:

Augustin de Bettignies
+33 1 69 19 41 54

contact@metabrainresearch.com